Singapore, May 13 -- stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, on 12 May 2020 announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company's mRNA vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2).

"Fast Track designation underscores the urgent need for a vaccine against the novel coronavirus," said Tal Zaks, M.D., Ph.D., Chief Medical Officer at Moderna. "As we await the full set of clinical data from the NIAID-led Phase 1 study, we are actively preparing for our Phase 2 and Phase 3 clinical studies to continue learning about the potential of mRNA-1273 to ...